Roivant Sciences ROIV
NASDAQ ROIV
$41.85 +0.66 (+1.60%)
At close: Nov 11, 2026 · 4:00 PM EST

Roivant Sciences (ROIV) Income from Discontinued Operations (2023 - 2026)

Updated

Roivant Sciences' Income from Discontinued Operations was $373.19 million in FY2025 (year ended Mar 31, 2025), compared with -$315.15 million in FY2024.

Analysis

Roivant Sciences (ROIV) Income from Discontinued Operations (2023 - 2026) Analysis & Trends

  • Per Business Quant data, Income from Discontinued Operations in earlier fiscal years was -$315.15 million in FY2024 and -$226.39 million in FY2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Discontinued) (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn -
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn -
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn -
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn -
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn -
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn -
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn -
10 Roivant Sciences 29.81 Bn 13.51 Bn 31.77 Mn 15.76 Mn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 15.76 Mn
Dec 31, 2024 327.02 Mn
Sep 30, 2024 -43.08 Mn
Jun 30, 2024 89.09 Mn
Mar 31, 2024 -87.54 Mn
Dec 31, 2023 -58.52 Mn
Sep 30, 2023 -86.48 Mn
API Access

Roivant Sciences Income from Discontinued Operations API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=income-from-discontinued-operations&ticker=ROIV&period=max&api_key=YOUR_API_KEY